Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Various Advanced Cancer 1Uveal Melanoma 1Urothelial Cancer 1Stomach Neoplasms 1Microsatellite Unstable Colorectal Cancer 1Mesothelioma 1Colorectal Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 5Fluorouracil 5Capecitabine 5pembrolizumab 3Cisplatin 3zolbetuximab 2Trastuzumab 2Nivolumab 2Leucovorin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1futibatinib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Stomach Neoplasms × Ipilimumab × Clear all
NCT02872116 2025-08-07

CheckMate649

Bristol-Myers Squibb

Phase 3 Completed
2,031 enrolled 19 charts 1 FDA
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡